Eli Lilly’s oral obesity drug Foundayo (orforglipron) won FDA approval, but the stock move quickly faded as investors weighed timing and competitive pricing versus Novo Nordisk’s oral Wegovy. Lilly shares rose 4% on the approval day before reversing into a 2% loss, reflecting uncertainty around sales ramp speed in the current oral GLP-1 landscape. The report highlights that Novo Nordisk received FDA approval for oral Wegovy in December and has already built momentum, with total prescriptions and filled prescriptions reported for the week ending March 20. Lilly plans to route Foundayo through its LillyDirect direct-to-consumer channels starting Monday, with tiered monthly pricing and insurance-based discounting. Analysts also focused on manufacturing economics, noting that tablet formulation could be less expensive than capsule versions studied in trials. The post-approval price competition and distribution execution appear to be the immediate watchpoints for biotech investors tracking GLP-1 expansion.